1. Therapy-related Myeloid Neoplasms in Children: A Single-institute Study
- Author
-
David R. Kelly, Geling Li, Taylor Holly, Andrew J. Carroll, Vishnu Reddy, Fady M. Mikhail, and Matthew A. Kutny
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Monosomy ,Myeloid ,Adolescent ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Myeloid Neoplasm ,Li-Fraumeni Syndrome ,Young Adult ,Germline mutation ,Internal medicine ,Rhabdomyosarcoma ,Humans ,Medicine ,Genetic Predisposition to Disease ,Child ,Myeloproliferative Disorders ,business.industry ,Noonan Syndrome ,Hematopoietic Stem Cell Transplantation ,Infant ,Neoplasms, Second Primary ,Hematology ,Allografts ,medicine.disease ,PTPN11 ,medicine.anatomical_structure ,Child, Preschool ,Hematologic Neoplasms ,Pediatrics, Perinatology and Child Health ,Chromosomes, Human, Pair 5 ,Noonan syndrome ,Female ,Chromosome Deletion ,business ,Chromosomes, Human, Pair 7 - Abstract
Therapy-related myeloid neoplasm (t-MN) in the pediatric population is not well characterized. We studied 12 pediatric patients diagnosed with t-MN in our institution since 2006. The median age at the t-MN diagnoses was 14.8 years (range, 9 to 20 y). The primary malignancies included 9 solid tumors and 3 hematopoietic malignancies. Rhabdomyosarcoma (n=4) was the most common primary malignancy. Five of the 9 patients with solid tumors and all 3 patients with hematopoietic malignancies had primary neoplasms involving bone marrow. The median latency period was 5.2 years (range, 1.8 to 13.8 y). Thrombocytopenia was present in all patients at the t-MN diagnoses. Complete or partial monosomy of chromosome 5 or 7 were the 2 most common cytogenetic abnormalities. A quarter of patients demonstrated a genetic predisposition to t-MN: 1 with Li-Fraumeni syndrome with a germline TP53 R248Q mutation, 1 with Noonan syndrome with a somatic mutation (PTPN11 S502T), and 1 with a constitutive chromosomal translocation [t(X;9)(p22;q34)] and a germline TP53 L130V mutation. Outcomes remain poor. Two patients survived 3 and 5.1 years after hematopoietic stem cell transplantation.
- Published
- 2021
- Full Text
- View/download PDF